Newsroom

OTTAWA, Ontario--(BUSINESS WIRE)--Winning Media...

PARIS--(BUSINESS WIRE)--  TotalEnergies SE: Information Concerning the Total Number of Voting Rights and Shares in the Share Capital as at November 30, 2025 (Article L.233-8-II of the French Commercial Code and article 223-16 of the General Regulation of the AMF) TotalEnergies SE (Paris:TTE) (LSE:TTE) (NYSE:TTE): Date Total number of shares Number of voting rights Theoretical (1) Exercisable (2) November 30, 2025 2,206,585,543 2,206,585,543 2,153,471,792 (1) In accordance with Article 223-11 of...

PARIS--(BUSINESS WIRE)--Regulatory News: TotalEnergies SE (Paris:TTE) (LSE:TTE) (NYSE:TTE): Date Total number of shares Number of voting rights Theoretical (1) Exercisable (2) November 30, 2025 2,206,585,543 2,206,585,543 2,153,471,792 (1) In accordance with Article 223-11 of the AMF General Regulation, this number is calculated on the basis of all the shares to which voting rights are attached, including shares for which voting rights have been suspended. (2) Total number of exercisable voting...

PARIS--(BUSINESS WIRE)--Regulatory News: TotalEnergies SE (Paris:TTE) (LSE:TTE) (NYSE:TTE): Date Nombre d'actions composant le capital Nombre de droits de vote Théoriques (1) Exerçables (2) 30 novembre 2025 2 206 585 543 2 206 585 543 2 153 471 792 (1) Conformément à l’article 223-11 du règlement général de l’Autorité des Marchés Financiers, ce nombre est calculé sur la base de l’ensemble des actions auxquelles sont attachés des droits de vote, y compris les actions privées de droit de vote. (2...

LONDON--(BUSINESS WIRE)--  FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Qube Research & Technologies Limited (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiari...

LONDON--(BUSINESS WIRE)--  FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Qube Research & Technologies Limited (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiari...

LONDON--(BUSINESS WIRE)--  FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Qube Research & Technologies Limited (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiari...

LONDON--(BUSINESS WIRE)--  FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Qube Research & Technologies Limited (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiari...

SAN CARLOS, Califórnia.--(BUSINESS WIRE)--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), uma empresa global de oncologia, anunciou hoje novos dados sobre sonrotoclax, um inibidor de BCL2 de próxima geração em investigação, demonstrando benefício clínico significativo como monoterapia e em combinação em malignidades de células B. Esses dados foram apresentados no 67º Encontro Anual & Exposição da Sociedade Americana de Hematologia (ASH) em Orlando, Flórida. As cinco apresentaç...

SAN CARLOS, Kalifornien--(BUSINESS WIRE)--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), ein weltweit tätiges Onkologieunternehmen, hat heute neue Daten zu Sonrotoclax veröffentlicht, einem in der Entwicklung befindlichen BCL2-Inhibitor der nächsten Generation, der als Monotherapie und in Kombination bei B-Zell-Malignomen einen bedeutenden klinischen Nutzen zeigt. Diese Daten wurden auf dem 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Flor...